This paper reviews the use of hyperfractionated and/or accelerated radiation therapy in the curative treatment of non-small cell lung cancer, and explains the scientific rationale behind the development of these regimes. The indications, practicalities and economics of introducing them routinely are addressed. Novel radiotherapy techniques are further discussed in the context of current developments and on-going clinical trials.
INTRODUCTION
The estimated average incidence of non-small cell lung cancer in Northern Ireland is over 750 new cases per year.1 Up to 20% ofpatients may be suitable for a surgical approach -of those who do have resection (estimated at less than 10% in Northern Ireland), fewer than half will be long term survivors. Tumour-related reasons for inoperability include local invasion and spread to mediastinal lymph nodes. Over the last 3 years, an annual average of 450 patients with lung cancer were referred to the Northern Ireland Centre for Clinical Oncology (NICCO). In 1994, 331 new lung cancer patients received radiotherapy treatment. Extrapolating from fractionation statistics, about 280 patients were treated for NSCLC, of which 38 received radical radiotherapy. This is in keeping with a recognised figure (~10%) for the proportion of patients referred for radiotherapy who have stage M/II disease and are suitable for small volume radical radiotherapy. Standard radical radiotherapy involves treating a planned volume once daily, five days per week, for up to 6 weeks. In the 30-40% who have unresectable locally advanced disease confined to the thorax, survival is of the order of 40% at one year and 15-20% at two years. Failure rates and patterns have been well documented, and indicate an intra-thoracic failure rate of up to 48%, depending on stage, histology and radiation dose delivered.2 Up to three-quarters of these failed with distant metastases, therefore the role of systemic chemotherapy continues to be widely studied. Nonetheless, many die of uncontrolled intra-thoracic disease and methods of improving the radiotherapy technique which might improve survival, need to be pursued. In recent years non-standard fractionation schedules have been studied in clinical trials for different disease sites. In 1997 a large multicentre prospective randomised controlled trial was reported in the Lancet describing a highly significant survival advantage for locally advanced NSCLC using CHART.3 This regime involves using smaller fraction sizes, three times per day for a continuous 12 day period. There are obvious practical and economic implications if this were to be made routinely available. The potential health gain in this common disease cannot be ignored. In conventional fractionation, doses of2 Gray are delivered once each day, five days per week.
Overall treatment times are normally around six weeks. In hyperfractionation, smaller doses per fraction are delivered two or three times per day, leaving the overall treatment time unchanged. This approach theoretically allows the total tumour dose to be escalated without increasing late morbidity, thereby improving the therapeutic index. In a recent review of hyperfractionated radiotherapy in human tumours, it was consistently demonstrated to be more effective in terms of responses than was conventional radiotherapy. However the methodology used to collate the information in this review has been critisized. 14 In accelerated radiotherapy, treatment is delivered in a shorter overall time, leaving the fraction size unchanged. The theory behind this is to reduce the amount of tumour cell repopulation during the treatment course. Several different strategies may be employed:
1. A straightforward short intensive coursetotal dose must be reduced because of otherwise significantly increased acute tissue toxicity. 2. Split-course technique -a rest period is introduced between the second and fourth week of treatment which allows acute normal tissue regeneration to occur so that total dose does not need to be reduced.
3. Concomitant boost technique -the second phase or small volume is given concurrently rather than sequentially.
4. Escalating dose -the total weekly dose is increased each week. It is thought that the regeneration of normal mucosa is stimulated early in the treatment course and might therefore be able to tolerate higher doses as the course is delivered. By combining hyperfractionation and accelerated radiotherapy, continuous hyperfractionated accelerated radiotherapy or CHART was developed, represented diagrammatically in Figure 2 , in order to maximise the potential gain. 15 This technique uses smaller multiple fractions per day and therefore a lower overall total dose. The acute tissue injury occurs only after the course is completed, and can therefore be allowed to heal and regenerate without the problem of having to complete treatment. The Radiation Therapy Oncology Group (RTOG) published a preliminary report of a prospective randomised study of various irradiation doses and fractionation schedules in the treatment of inoperable carcinoma of the lung, in 1980.16 Radiological complete response (CR) rate was 10-25%, and 2-year survival only 12%. From this, the exploration of novel radiotherapy schedules has mushroomed, in a determined effort to find the optimum scheduling. Laboratory studies have played a huge part in painstakingly and scientifically providing the basis of clinical studies.
METHODS
The literature was reviewed using Medline, and authoritative texts reviewed. A search was conducted for all papers and specifically all clinical trials in hyperfractionated or accelerated radiotherapy. Fewer than 15 figure 1 ) and subgroup analysis indicated that the largest benefit for the accelerated regime occurred in the 82% of patients who had squamous cell carcinoma. In this subgroup, 2-year survival increased from 19% to 33%. Overall, there were no significant differences in acute or late morbidity. As a follow-on from this, CHARTWEL (CHART weekend-less) is being piloted with a view to maintaining the radiobiological advantage whilst producing less interference with normal working patterns.
ECONOMIC AND STAFFING IMPLICATIONS
The cost of treating with a course of radiotherapy has not generally been a significant part of overall analyses before, but then recommending routine out-ofhours radiotherapy treatments has not until now, been a prominent issue.34 It has been argued however, that sub-optimal radiotherapy is more costly in the long run.35 CHART was used in 10 UK centres during the 2 major trials for both bronchus and for head and neck cancer. The cost of CHART versus conventional radiotherapy was compared,'7 and CHART was not suprisingly found to be more expensive. However, for NSCLC, the difference was calculated to be £698 per patient (less if a hostel ward is available, which is the case at NICCO). If CHARTWEL proves to be as effective as CHART, then not only would the cost be reduced further, but the important issue of staff working times would not be as significant. It is also acknowledged that these costs relate only to treatment, and not to the longer term gain ofdisease-free or overall survival which in turn reduces the need for palliative and supportive care facilities. The idea of optimising radiotherapy either by fractionation schedules, beam shaping, or both, is now the focus of many studies. The selection of patients most likely to benefit from these techniques is crucial, and it may be that using specific assays to determine clonogen doubling time, patients could be more accurately selected for CHART (short Tpot) or concomitant boost accelerated radiotherapy (longer Tpot).49' 50Other ways to enhance the tumour kill effect ofradiation are with the use of radiosensitisers such as misonidazole,5' or the concurrent breathing of carbogen and nicotinamide,52 but these techniques remain experimental. Intraluminal brachytherapy (or radiation delivered from a source, rather than external beams) is also of interest, but as yet has no defined place in the radical treatment of NSCLC.
An interesting concept that is currently under investigation, is bio-effective dosimetry.53 This has potential to produce treatment plans based on biological effect, rather than absorbed dose, to any given point. Although there is a long way to go before this could be introduced to clinical departments, it is one of the many ways in which the planning and delivery of radiation may be yet further advanced.
CHEMOTHERAPY FOR NON-SMALL CELL LUNG CANCER
The place of systemic chemotherapy in NSCLC has been widely investigated, and there is now evidence that a modest survival advantage can be achieved.54 Many investigators are therefore looking at chemo-radiotherapy combinations, using platinum-based chemotherapy and intensive fractionation,55 however there are still reasonable concerns about toxicity.56 Similarly, with increasing evidence of benefit for combined treatment in unresectable oesophageal carcinoma,57 the possibility of enhancing local control even further with intensified radiotherapy needs to be investigated. Indeed, the ultimate search for a combination of optimised radiotherapy and the most effective systemic chemotherapy in unresectable tumours, provides considerable material for on-going and future clinical trials.
CONCLUSIONS
While results of surgical resection for early tumours are good this disease has a poor prognosis controlling intra-thoracic tumour in this common disease should be a priority in cancer research and management. Of many possible ways, and combinations of ways, to approach this problem, CHART has shown a statistically significant benefit in a large multi-centre randomised controlled trial. However, adopting this technique into routine clinical practice requires more resources and careful patient selection.58 Two years on after publication, only a few UK Centres find themselves able to offer CHART to selected patients, and the reasons for this are clearly outlined in a recent editorial. 59 The bottom line includes difficulties in changing departmental working hours, and lack of financial support.
There is no real doubt that it ought to be made available; however the practicalities of its introduction as an available standard, should not be underestimated. Novel and developing radiation therapy must be incorporated as an intregal part of modern cancer management. It is essential that participation in national clinical trials is encouraged, that radiotherapy techniques are optimised, and that combined modality approaches are able to be fully supported.
